Japan: JBA Omics Analysis Technology in Bioengineering Seminar "NGS for Adventitious Agent Detection and Critical Quality Attribute Assessment in Biopharmaceuticals"

Genedata will give a talk at Omics Analysis Technology in Bioengineering Seminar "NGS for Adventitious Agent Detection and Critical Quality Attribute Assessment in Biopharmaceuticals" hosted by Japan Bioindustry Association. 

Next-Generation Sequencing (NGS) is a transformative option for adventitious agent detection and critical quality attribute assessment due to its speed, sensitivity, and unbiased nature. Maintaining in-process critical quality attributes (CQAs) is necessary to ensure the timely delivery of safe and effective biologically derived therapeutics. Currently used approaches for monitoring CQAs have limitations that are solvable with next-generation sequencing (NGS). Genedata Selector® is an end-to-end enterprise software solution streamlining NGS-based assays for vaccine, antibodies, Advanced Therapy Medicinal Product (ATMP) development and manufacturing. The software automates and standardizes NGS-based assays and bringing life-changing treatments to production faster.

To receive more information about Genedata in Japanese, please contact japan(at)genedata.com.

Presentation Overview

NGS for Adventitious Agent Detection and Critical Quality Attribute Assessment: Considerations and Outcomes
Thomas Hartsch, Ph.D., Head of Genedata Selector Business Unit, Genedata AG
Thursday, June 22, 2023  |  14:00–15:30 JST